Biotech, large pharma, generics, medical devices, diagnostics and insurers.
| Symbol | Company | Industry | Price | 1‑day | 1‑month |
|---|---|---|---|---|---|
| LLY | Eli Lilly | Drug Manufacturers - General | $1,186 | -0.52% | -2.57% |
| JNJ | Johnson & Johnson | Drug Manufacturers - General | $259.24 | +0.88% | +0.05% |
| ABBV | AbbVie | Drug Manufacturers - General | $246.04 | +0.89% | -0.85% |
| UNH | UnitedHealth Group | Healthcare Plans | $407.08 | +0.77% | -5.70% |
| MRK | Merck | Drug Manufacturers - General | $128.58 | +0.16% | +2.81% |
| AMGN | Amgen | Drug Manufacturers - General | $410.95 | +1.51% | +13.02% |
| ABT | Abbott Laboratories | Medical Devices | $107.81 | -0.14% | +15.02% |
| GILD | Gilead Sciences | Drug Manufacturers - General | $133.21 | +1.80% | -1.21% |
| PFE | Pfizer | Drug Manufacturers - General | $26.76 | +2.14% | +12.28% |
| VRTX | Vertex Pharmaceuticals | Biotechnology | $496.07 | +2.49% | -0.09% |
| REGN | Regeneron Pharmaceuticals | Biotechnology | $784.36 | +1.59% | +17.43% |
| NTRA | Natera | Diagnostics & Research | $322.10 | +21.37% | +14.28% |
| BIIB | Biogen | Drug Manufacturers - General | $207.94 | +0.80% | +4.54% |
| ILMN | Illumina | Diagnostics & Research | $187.96 | -2.97% | -2.99% |
| BNTX | BioNTech | Biotechnology | $93.67 | +2.72% | +0.74% |
| MRNA | Moderna | Biotechnology | $59.17 | +9.86% | -22.71% |
| TXG | 10x Genomics | Health Information Services | $52.03 | +14.10% | +20.72% |
| CRSP | CRISPR Therapeutics | Biotechnology | $53.52 | +3.64% | -5.01% |
| BEAM | Beam Therapeutics | Biotechnology | $27.48 | +0.84% | -23.28% |
| RXRX | Recursion Pharmaceuticals | Biotechnology | $3.22 | +1.26% | -14.36% |
| NTLA | Intellia Therapeutics | Biotechnology | $11.94 | +6.23% | -22.67% |
| NVAX | Novavax | Biotechnology | $7.95 | +2.71% | -15.43% |
| CRON | Cronos Group | Drug Manufacturers - Specialty & Generic | $3.10 | +0.98% | +11.51% |
| SANA | Sana Biotechnology | Biotechnology | $3.52 | +3.23% | -10.43% |
| TLRY | Tilray Brands | Drug Manufacturers - Specialty & Generic | $4.57 | +2.93% | +4.10% |
| EDIT | Editas Medicine | Biotechnology | $2.88 | -0.69% | -12.73% |
| CGC | Canopy Growth | Drug Manufacturers - Specialty & Generic | $0.9700 | +4.08% | -0.41% |
| ACB | Aurora Cannabis | Drug Manufacturers - Specialty & Generic | $2.99 | +0.34% | +10.74% |
| OGI | Organigram Global | Drug Manufacturers - Specialty & Generic | $0.9900 | +0.00% | +0.92% |
Healthcare splits into two populations that share almost nothing beyond a regulator. On one side are large pharmaceutical companies, device makers, diagnostics firms and insurers — profitable, cash-generative businesses whose central problem is what replaces the revenue that goes away when a patent expires. On the other are clinical- stage biotechnology companies with no approved product, no revenue, and a valuation that is a probability-weighted guess about a trial that has not reported yet.
For the first group, the standard fundamental questions apply and the answers mean something. For the second, the only figures that matter are cash on hand, quarterly burn rate, and the resulting runway in months against the date of the next readout. A company with two years of cash and a phase III result due in eight months is in a very different position from one with the same pipeline and six months of cash, and no margin or return metric will tell you which is which.
3 industries have enough coverage for a dedicated page. The rest are listed for completeness.
Binary events. A single readout can re-rate a developmental company by a large multiple in either direction, and no amount of financial analysis anticipates the result.
Loss of exclusivity on a major product removes most of its revenue within a couple of years as generics enter. The dates are public and the effect is predictable in timing if not in magnitude.
Revenue depends on what public and private payers agree to reimburse, which is a political variable rather than a commercial one.
Approvals, rejections and label changes are set by agency timetables that operate independently of the business cycle.
The five-factor screen assumes a company with revenue, margins and equity to measure returns against. Applied to a pre-revenue biotechnology company it produces a score from inputs that do not describe the business. On those names, cash runway against the next catalyst is the relevant reading and the screen is not.
Want a full fundamental breakdown on one of these companies?
Generate a free reportPrices shown are end-of-session closing values from the most recent completed trading day and are refreshed periodically, not in real time. Sector and industry classifications follow the labels reported by our market data provider and can differ from other schemes. This page is informational and is not investment advice.